.Statement of Financial Position, Assets Quarterly Data
Difficulty: Beginner
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.
Amgen Inc., Consolidated Statement of Financial Position, Assets (quarterly data)
USD $ in millions
| Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||
| | Marketable securities | ||||||||||||||||||||||||||||||||||||||||||
| | Receivable from sale of investments | ||||||||||||||||||||||||||||||||||||||||||
| | Trade receivables, net | ||||||||||||||||||||||||||||||||||||||||||
| | Inventories | ||||||||||||||||||||||||||||||||||||||||||
| | Other current assets | ||||||||||||||||||||||||||||||||||||||||||
| | Current assets | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||
| | Property, plant and equipment, net | ||||||||||||||||||||||||||||||||||||||||||
| | Intangible assets, net | ||||||||||||||||||||||||||||||||||||||||||
| | Goodwill | ||||||||||||||||||||||||||||||||||||||||||
| | Restricted investments | ||||||||||||||||||||||||||||||||||||||||||
| | Other assets | ||||||||||||||||||||||||||||||||||||||||||
| | Noncurrent assets | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||
| | Total assets | | | | | | | | | | | | | | | | | | | | | |
| Item | Description | The company |
|---|---|---|
| Cash and cash equivalents | Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. | Amgen Inc.'s cash and cash equivalents increased from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018. |
| Marketable securities | Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer. | Amgen Inc.'s marketable securities declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018. |
| Trade receivables, net | Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. | Amgen Inc.'s trade receivables, net declined from Q3 2017 to Q4 2017 but then increased from Q4 2017 to Q1 2018 exceeding Q3 2017 level. |
| Inventories | Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). | Amgen Inc.'s inventories declined from Q3 2017 to Q4 2017 but then increased from Q4 2017 to Q1 2018 exceeding Q3 2017 level. |
| Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Amgen Inc.'s current assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018. |
| Property, plant and equipment, net | Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. | Amgen Inc.'s property, plant and equipment, net increased from Q3 2017 to Q4 2017 but then slightly declined from Q4 2017 to Q1 2018 not reaching Q3 2017 level. |
| Noncurrent assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Amgen Inc.'s noncurrent assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018. |
| Total assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Amgen Inc.'s total assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018. |
